The Honest Guide to Trulicity: What Patients and Doctors Actually Say

Trulicity at a glance:

• Drug class: GLP-1 receptor agonist
• Manufacturer: Eli Lilly
• FDA approved: 2014
• Route: subcutaneous injection (single-dose pen)
• Typical frequency: once weekly
• Half-life: approximately 5 days
• Cash price (US): ~$987/month list; commercial savings card available
• Receptor target: GLP-1 receptor

Let's cut through the marketing on Trulicity and look at what the data actually say. Dulaglutide is a long-acting GLP-1 analog fused to a human IgG4 Fc fragment, extending half-life to enable weekly dosing, and the result for users is: a1c reduction of ~1.0–1.5% and weight loss of 2–4 kg at higher doses.

What is Trulicity?

Dulaglutide is a long-acting GLP-1 analog fused to a human IgG4 Fc fragment, extending half-life to enable weekly dosing.

Trulicity is manufactured by Eli Lilly. Trulicity was approved by the FDA in 2014. Its approved indications include type 2 diabetes, cardiovascular risk reduction in T2D adults with established CVD or risk factors. Off-label use happens in clinical practice but is the prescriber's responsibility.

The drug class glp-1 receptor agonist works by acting at the GLP-1 receptor. We cover the details below.

How Trulicity Works in the Body

Dulaglutide is a long-acting GLP-1 analog fused to a human IgG4 Fc fragment, extending half-life to enable weekly dosing. The receptor target — GLP-1 receptor — drives the downstream effects users care about: a1c reduction of ~1.0–1.5% and weight loss of 2–4 kg at higher doses.

The pharmacokinetics matter for daily use. Trulicity has a half-life of approximately 5 days, which determines how often it is dosed. The standard route of administration is subcutaneous injection (single-dose pen), and the typical schedule is once weekly.

For more detail on the underlying biology, see our breakdown of how Trulicity works.

Who Uses Trulicity?

Trulicity is most relevant for people whose situation maps to its approved indications: type 2 diabetes; cardiovascular risk reduction in T2D adults with established CVD or risk factors.

People who should avoid Trulicity include those with the following:

• personal/family history of medullary thyroid cancer
• MEN 2

Common and Serious Side Effects

The most commonly reported side effects of Trulicity include:

• nausea
• diarrhea
• vomiting
• decreased appetite

Serious risks — uncommon but worth knowing — include:

• pancreatitis
• thyroid C-cell tumors (boxed warning)
• gallbladder disease

We have a more detailed breakdown in our Trulicity side-effects guide.

Trulicity vs Alternatives

Other GLP-1 agonists include Ozempic (semaglutide), Mounjaro/Zepbound (tirzepatide), and Victoza (liraglutide). If you are weighing Trulicity against another option, our comparison pages include Trulicity Side Effects: 7 Things to Watch For (and How to Manage Them), Trulicity Results: What the Real Numbers Show in 2026, Why Trulicity Costs So Much (and 5 Ways to Pay Less).

Bottom Line

If you're considering Trulicity, the most useful next step is usually a conversation with a clinician who knows the full landscape of options — not just the one they prescribe most often. Multiple randomized controlled trials support its efficacy. If you are considering Trulicity, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• Trulicity Side Effects: 7 Things to Watch For (and How to Manage Them)
• Trulicity Results: What the Real Numbers Show in 2026
• Why Trulicity Costs So Much (and 5 Ways to Pay Less)
• Trulicity and Weight Loss: What Trials Show vs. Real Life
• What Is Ozempic? Everything You Should Know Before Starting
• Is Ozempic Safe? An Honest Look at the Side-Effect Profile

Sources

• Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221.
• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989.
• Marso SP et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6). NEJM 2016;375:1834.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.